FDA Focusing Enforcement Efforts on GMP Compliance As Off-Label Prosecutions Wane
This article was originally published in The Gold Sheet
Executive Summary
With recent court decisions largely stripping FDA of its powers to take pharmaceutical manufacturers to court for promoting off-label uses, the agency is shifting its enforcement focus to GMP violations, says attorney.
You may also be interested in...
Vascular Solutions Not-Guilty Verdict Another Challenge To FDA Off-Label Oversight
The case against the venous device manufacturer turned on the rights of manufacturers to use truthful off-label speech to promote their products. It joins a growing body of cases in which courts have sanctioned broader off-label speech than has traditionally been allowed by FDA.
FDA Seeks To Resolve First Amendment Suit By Pacira
Judge extends date for agency response to firm's complaint as parties continue settlement talks; case reveals two chinks in FDA’s off-label regulatory regime armor, former FDA advisor says.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”